DE69628864D1 - Invertierte chimäre und hybrid-oligonukleotide - Google Patents

Invertierte chimäre und hybrid-oligonukleotide

Info

Publication number
DE69628864D1
DE69628864D1 DE69628864T DE69628864T DE69628864D1 DE 69628864 D1 DE69628864 D1 DE 69628864D1 DE 69628864 T DE69628864 T DE 69628864T DE 69628864 T DE69628864 T DE 69628864T DE 69628864 D1 DE69628864 D1 DE 69628864D1
Authority
DE
Germany
Prior art keywords
inverted
oligonucleotides
chimeral
hybrid
hybrid oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628864T
Other languages
English (en)
Other versions
DE69628864T2 (de
Inventor
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DE69628864D1 publication Critical patent/DE69628864D1/de
Publication of DE69628864T2 publication Critical patent/DE69628864T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
DE69628864T 1995-08-17 1996-08-16 Invertierte chimäre und hybrid-oligonukleotide Expired - Lifetime DE69628864T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US516454 1995-08-17
US08/516,454 US5652356A (en) 1995-08-17 1995-08-17 Inverted chimeric and hybrid oligonucleotides
PCT/US1996/013371 WO1997006662A2 (en) 1995-08-17 1996-08-16 Inverted chimeric and hybrid oligonucleotides

Publications (2)

Publication Number Publication Date
DE69628864D1 true DE69628864D1 (de) 2003-07-31
DE69628864T2 DE69628864T2 (de) 2004-05-06

Family

ID=24055671

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69628864T Expired - Lifetime DE69628864T2 (de) 1995-08-17 1996-08-16 Invertierte chimäre und hybrid-oligonukleotide
DE69637718T Expired - Lifetime DE69637718D1 (de) 1995-08-17 1996-08-16 Invertierte Chimäre und Hybrid-Oligonukleotide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637718T Expired - Lifetime DE69637718D1 (de) 1995-08-17 1996-08-16 Invertierte Chimäre und Hybrid-Oligonukleotide

Country Status (11)

Country Link
US (3) US5652356A (de)
EP (2) EP1340765B1 (de)
JP (1) JP4177455B2 (de)
AT (2) ATE411333T1 (de)
AU (1) AU6953896A (de)
CA (1) CA2229811C (de)
DE (2) DE69628864T2 (de)
DK (1) DK1019428T3 (de)
ES (2) ES2315442T3 (de)
PT (1) PT1019428E (de)
WO (1) WO1997006662A2 (de)

Families Citing this family (419)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
US6291667B1 (en) 1997-01-31 2001-09-18 Parkash S. Gill Method and composition for treatment of kaposi's sarcoma
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6489304B2 (en) * 1997-05-01 2002-12-03 Hybridon, Inc. Hyperstructure-forming carriers
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO1999009154A2 (en) * 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
US6013786A (en) * 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6306831B1 (en) 1997-09-12 2001-10-23 Qik Technologies, Inc. Transplacental delivery of oligonucleotides
US6127535A (en) * 1997-11-05 2000-10-03 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
WO2000018885A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US20010049436A1 (en) * 1998-04-01 2001-12-06 Wen-Qiang Zhou Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
WO1999054459A2 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
AU745880B2 (en) 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
WO1999060167A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6127124A (en) 1999-01-20 2000-10-03 Isis Pharmaceuticals, Inc. Fluorescence based nuclease assay
US20030220486A1 (en) * 1999-04-01 2003-11-27 Wen-Qiang Zhou Mixed backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
CA2784789A1 (en) * 1999-08-13 2001-02-22 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
AU2001298014A1 (en) 2000-03-24 2003-01-29 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001249817A1 (en) * 2000-04-03 2001-10-15 Hybridon, Inc. Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7846733B2 (en) * 2000-06-26 2010-12-07 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
US8178304B2 (en) * 2000-10-06 2012-05-15 Smith Terry J Diagnostic methods relating to Graves' disease and other autoimmune disorders
DE60142709D1 (de) 2000-12-13 2010-09-09 Nugen Technologies Inc Methoden und zusammensetzungen zur generierung einer vielzahl von kopien von nukleinsäuresequenzen und methoden zur detektion derselben
US20030148970A1 (en) * 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
US20030152557A1 (en) * 2001-01-12 2003-08-14 Besterman Jeffrey M. Methods for inhibiting histone deacetylase-4
ZA200210369B (en) * 2001-03-09 2004-07-08 Nugen Technologies Inc Methods and compositions for amplification or RNA sequences.
JP2005508135A (ja) * 2001-03-09 2005-03-31 ニューゲン テクノロジーズ， インコーポレイテッド Ｒｎａ配列の増幅のための方法および組成物
CA2446606A1 (en) * 2001-05-11 2002-11-21 Methylgene, Inc. Inhibitors of dna methyltransferase isoforms
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
EP2270024B1 (de) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US20040266718A1 (en) * 2001-08-06 2004-12-30 Zuomei Li Inhibition of specific histone deacetylase isoforms
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US20030096781A1 (en) * 2001-08-31 2003-05-22 University Of Southern California IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
ATE516364T1 (de) 2001-10-09 2011-07-15 Isis Pharmaceuticals Inc Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
WO2003054143A2 (en) * 2001-10-25 2003-07-03 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
ITMI20012367A1 (it) * 2001-11-09 2003-05-09 Visufarma S R L Oligonucleotidi antisenso che regolano l'espressione del gene antiapoptotico bcl-2
JP2005518195A (ja) * 2001-11-27 2005-06-23 ワシントン・ユニバーシティ 治療用タンパク質および治療方法
US20040091893A1 (en) * 2001-11-27 2004-05-13 Jeffrey Gordon Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
JP2005520511A (ja) * 2002-03-18 2005-07-14 ガミダ セル リミテッド エクスビボ拡大培養された幹細胞における分化を誘導する方法
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20030220844A1 (en) * 2002-05-24 2003-11-27 Marnellos Georgios E. Method and system for purchasing genetic data
AU2003231912A1 (en) * 2002-06-12 2003-12-31 Tel Aviv Medical Center Research Development Fund Methods of detecting and treating prostate cancer
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
AU2003301353A1 (en) * 2002-10-18 2004-05-04 Cylene Pharmaceuticals Processes for identifying quadruplex-targeted antiviral molecules
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044136A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
AU2003287505A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
ES2417879T3 (es) 2002-11-13 2013-08-09 Genzyme Corporation Modulación antisentido de la expresión de la apolipoproteína B
EP2336318B1 (de) 2002-11-13 2013-04-24 Genzyme Corporation Antisense-modulation von apolipoprotein-b-expression
DE60329526D1 (de) 2002-11-15 2009-11-12 Morphotek Inc Verfahren zur erzeugung einer hohen antikörperproduktion von durch in-vitro-immunisierung entstandenen hybridomen
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
US7371840B2 (en) 2003-01-08 2008-05-13 The University Of Southern California Isolation and characterization of ECA1, a gene overexpressed in endometrioid carcinomas of ovary and endometrium
ES2400033T3 (es) 2003-02-11 2013-04-05 Antisense Therapeutics Ltd Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004092418A2 (en) * 2003-04-14 2004-10-28 Nugen Technologies, Inc. Global amplification using a randomly primed composite primer
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
EP1644475A4 (de) * 2003-06-20 2009-06-03 Isis Pharmaceuticals Inc Doppelstrang-zusammensetzungen mit einem 3'-endo-modifizierten strang zur verwendung bei der genmodulation
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050095627A1 (en) * 2003-09-03 2005-05-05 The Salk Institute For Biological Studies Multiple antigen detection assays and reagents
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
TW200519202A (en) 2003-09-18 2005-06-16 Lilly Co Eli Modulation of eIF4E expression
CN1882602B (zh) 2003-10-10 2011-02-09 阿尔卡米亚肿瘤股份有限公司 在疾病治疗中乙酰透明质酸合成的调节和降解
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
DK2161283T3 (da) 2003-11-17 2014-09-01 Genentech Inc SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
US7741070B2 (en) * 2003-12-24 2010-06-22 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
WO2005062923A2 (en) * 2003-12-24 2005-07-14 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
US7608699B2 (en) * 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
WO2005071080A2 (en) 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
DE602005017362D1 (de) * 2004-02-06 2009-12-10 Dharmacon Inc Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1730309B1 (de) * 2004-03-15 2016-05-04 Ionis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur optimierung der spaltung von rna durch rnase h
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP1737878A2 (de) 2004-04-05 2007-01-03 Alnylam Pharmaceuticals Inc. Verfahren und reagentien für die synthese und aufreinigung von oligonukleotiden
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP2008501693A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
HUE026284T2 (en) 2004-08-10 2016-06-28 Genzyme Corp Oligonucleotides for use in modulating lipoprotein and cholesterol levels in humans
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
NZ554277A (en) 2004-10-20 2010-09-30 Antisense Therapeutics Ltd Antisense modulation of integrin alpha 4 expression
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
EP1864134A4 (de) * 2005-02-07 2010-10-20 Univ Columbia Verfahren zur behandlung oder vorbeugung von hormonresistentem prostatakrebs unter verwendung von für protocadherin-pc spezifischer sirna oder anderer inhibitoren der protocadherin-pc-expression oder -aktivität
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
CA2606270A1 (en) 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
EP1891141B1 (de) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007030759A2 (en) 2005-09-07 2007-03-15 Nugen Technologies, Inc. Improved nucleic acid amplification procedure
EP1924692A2 (de) * 2005-09-16 2008-05-28 Coley Pharmaceutical GmbH Modulierung von immunanregenden eigenschaften von short-interfering-ribonukleinsäure (sirna) durch nukleotidmodifizierung
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
US7807652B2 (en) 2005-11-21 2010-10-05 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
JP5425474B2 (ja) 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド ハンチンチン対する、組成物及びその使用
CA2640171C (en) * 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
AU2007258117B2 (en) 2006-05-05 2013-05-30 Isis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
ES2389737T3 (es) * 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
WO2008036825A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
EP1935428A1 (de) * 2006-12-22 2008-06-25 Antisense Pharma GmbH Oligonukleotid-Polymer Konjugate
MX2009008470A (es) 2007-02-09 2009-11-26 Univ Northwestern Particulas para detectar objetivos intracelulares.
EP2144633B1 (de) * 2007-04-23 2014-07-16 Deliversir Ltd System zur Abgabe von therapeutischen Mitteln in lebenden Zellen und Zellkernen
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
DK2826863T3 (en) 2007-05-30 2017-12-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (de) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbozyklische bizyklische nukleinsäureanaloga
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US8278283B2 (en) * 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
KR101654007B1 (ko) 2007-08-15 2016-09-05 아이오니스 파마수티컬즈, 인코포레이티드 테트라하이드로피란 핵산 유사체
WO2009039442A1 (en) 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US8637478B2 (en) * 2007-11-13 2014-01-28 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
EP2222851B1 (de) 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation der cd40-expression
WO2009067647A1 (en) * 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US20100119528A1 (en) * 2008-01-17 2010-05-13 Gobinda Sarkar Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus
EP2620511B1 (de) 2008-01-17 2018-02-28 Sequenom, Inc. Einzelmolekül-Nukleinsäurensequenzanalyseverfahren
EP2265627A2 (de) * 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclische cyclohexitolnukleinsäureanaloga
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US20090203531A1 (en) * 2008-02-12 2009-08-13 Nurith Kurn Method for Archiving and Clonal Expansion
EP2271772B1 (de) * 2008-03-11 2014-07-16 Sequenom, Inc. Tests auf nukleinsäurebasis zur pränatalen geschlechtsbestimmung
WO2009117589A1 (en) 2008-03-21 2009-09-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
GB2470672B (en) 2008-03-21 2012-09-12 Nugen Technologies Inc Methods of RNA amplification in the presence of DNA
US9290534B2 (en) * 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
US20110262485A1 (en) 2008-08-04 2011-10-27 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
DK2331141T3 (en) 2008-08-25 2016-04-04 Excaliard Pharmaceuticals Inc Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) * 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8604192B2 (en) * 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
EP2356129B1 (de) * 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituierte alpha-l-bicyclische nukleoside
KR101979134B1 (ko) 2008-10-15 2019-05-15 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
KR101692880B1 (ko) 2008-11-24 2017-01-04 노오쓰웨스턴 유니버시티 다가 ｒｎａ-나노입자 구조체
MX2011005910A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
KR101840618B1 (ko) 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CN102307997B (zh) 2008-12-04 2018-03-30 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
CA2746508A1 (en) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010081049A1 (en) * 2009-01-08 2010-07-15 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
KR101546673B1 (ko) * 2009-01-15 2015-08-25 삼성전자주식회사 전자 사진용 토너 및 그의 제조방법
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
CN102387817B (zh) 2009-02-12 2018-01-30 库尔纳公司 通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病
WO2010093906A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US20110319317A1 (en) 2009-03-04 2011-12-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
CA2755404C (en) 2009-03-17 2020-03-24 Joseph Collard Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
NO2424987T3 (de) 2009-05-01 2018-04-14
CN102803492B (zh) 2009-05-06 2016-06-29 库尔纳公司 通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
EP2427553A4 (de) 2009-05-06 2012-11-07 Opko Curna Llc Behandlung von lipidtransport- und stoffwechselgenbedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein lipidtransport- und stoffwechselgen
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
KR101801404B1 (ko) 2009-06-16 2017-12-20 큐알엔에이, 인크. 콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
KR101807323B1 (ko) 2009-06-24 2017-12-08 큐알엔에이, 인크. Ｔｎｆｒ2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(ｔｎｆｒ2) 관련된 질환의 치료
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
HUE026708T2 (en) 2009-07-14 2016-07-28 Mayo Foundation Peptide-mediated, non-covalent delivery of active substances in blood glucose
ES2585360T3 (es) 2009-08-05 2016-10-05 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
EP2462153B1 (de) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclische cyclohexosenukleinsäureanaloga
JP5964232B2 (ja) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド ‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
HUE026020T2 (en) 2009-08-27 2016-05-30 Idera Pharmaceuticals Inc Preparation for inhibiting gene expression and its uses
EP2473522B1 (de) 2009-09-02 2016-08-17 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
EP2494075B1 (de) 2009-10-30 2018-04-04 Northwestern University Templatgesteuerte nanokonjugate
KR101944119B1 (ko) 2009-11-13 2019-01-30 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
CN103755809B (zh) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
CA2782366A1 (en) 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
ES2577017T3 (es) 2009-12-22 2016-07-12 Sequenom, Inc. Procedimientos y kits para identificar la aneuploidia
CA2782373C (en) 2009-12-23 2019-03-26 Opko Curna, Llc Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
EP2515947B1 (de) 2009-12-23 2021-10-06 CuRNA, Inc. Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
EP2519633B1 (de) 2009-12-29 2017-10-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
EP2519634B1 (de) 2009-12-29 2016-06-01 CuRNA, Inc. Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
JP5886757B2 (ja) 2010-01-04 2016-03-16 カッパーアールエヌエー，インコーポレイテッド インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
DK2529015T3 (en) 2010-01-25 2018-02-26 Curna Inc TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
JP5976548B2 (ja) 2010-02-22 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
TW201437228A (zh) 2010-02-23 2014-10-01 Genentech Inc 用於診斷及治療腫瘤之組合物及方法
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011112732A2 (en) 2010-03-12 2011-09-15 The Brigham And Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
WO2011113015A2 (en) 2010-03-12 2011-09-15 Avi Biopharma, Inc. Antisense modulation of nuclear hormone receptors
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
EP2625186B1 (de) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP2563912B1 (de) 2010-04-29 2018-09-05 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von asparaginyl-trna-synthetasen
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
BR112012027547B1 (pt) 2010-04-29 2022-06-14 Ionis Pharmaceuticals, Inc Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
KR101936011B1 (ko) 2010-05-03 2019-01-07 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
JP5866106B2 (ja) 2010-05-12 2016-02-17 コロンビア ユニヴァーシティ インスリンを産生し分泌する腸内分泌細胞の製造方法
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ， インコーポレイテッド ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
EP2608801B1 (de) 2010-08-25 2019-08-21 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
JP6049623B2 (ja) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
CN103201387B (zh) 2010-10-27 2018-02-02 库尔纳公司 通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
CA2817960C (en) 2010-11-17 2020-06-09 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012097261A2 (en) 2011-01-14 2012-07-19 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
US9243034B2 (en) 2011-01-27 2016-01-26 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
EP2668200B1 (de) 2011-01-27 2017-03-15 Ramot at Tel-Aviv University Ltd. Inhibitoren vom lycogen-synthase-kinase-3
AU2012212110A1 (en) 2011-02-02 2013-08-01 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
CN103391777A (zh) 2011-02-02 2013-11-13 普林斯顿大学理事会 作为病毒产生调节剂的去乙酰化酶调节剂
US8877722B2 (en) 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
US8460872B2 (en) 2011-04-29 2013-06-11 Sequenom, Inc. Quantification of a minority nucleic acid species
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
JP2014526517A (ja) 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ 血液脳関門を通過することができるナノ抱合体
WO2013055865A1 (en) 2011-10-11 2013-04-18 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
JP2015502365A (ja) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
EP2820129A1 (de) 2012-03-02 2015-01-07 Sequenom, Inc. Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
WO2013138374A2 (en) 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2839005B1 (de) 2012-04-20 2021-01-06 Aptamir Therapeutics, Inc. Mirna-modulatoren von thermogenese
EA201492123A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов smn
EP3511416A1 (de) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Zusammensetzungen und verfahren zur modulation von genexpression
JP2015519899A (ja) 2012-05-21 2015-07-16 ザ スクリプス リサーチ インスティテュート リボソームポリヌクレオチドおよび関連する発現系
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
AU2013290102B2 (en) 2012-07-13 2018-11-15 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US20150216892A1 (en) 2012-08-03 2015-08-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
EP2885312A4 (de) 2012-08-15 2016-01-20 Isis Pharmaceuticals Inc Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kappungsprotokollen
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
EP2971100A1 (de) 2013-03-13 2016-01-20 Sequenom, Inc. Primer zur analyse der dna-methylierung
NZ631512A (en) 2013-05-01 2016-10-28 Ionis Pharmaceuticals Inc Compositions and methods for modulating apolipoprotein (a) expression
ES2862125T3 (es) 2013-06-13 2021-10-07 Antisense Therapeutics Ltd Terapia combinada para acromegalia
WO2014207743A2 (en) 2013-06-24 2014-12-31 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
WO2015117010A2 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
CN116970607A (zh) 2014-03-19 2023-10-31 Ionis制药公司 用于调节共济失调蛋白2表达的组合物
EP3757214B1 (de) 2014-04-01 2022-06-15 Biogen MA Inc. Zusammensetzungen zur modulierung der sod-1-expression
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3608406B1 (de) 2014-05-01 2023-02-15 Ionis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur modulation der expression vom komplementfaktor b
JP6851201B2 (ja) 2014-06-10 2021-03-31 エラスムス ユニバーシティ メディカルセンター ロッテルダムＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｒｏｔｔｅｒｄａｍ ポンペ病の治療に有用なアンチセンスオリゴヌクレオチド
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
WO2015200901A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3663403A1 (de) 2014-09-26 2020-06-10 University of Massachusetts Rna-modulierende stoffe
JP2017537619A (ja) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ 球状核酸ナノ粒子複合体の配列特異的細胞内取込
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
GB201507926D0 (en) * 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides
JP2018518491A (ja) 2015-06-12 2018-07-12 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3314250A4 (de) 2015-06-26 2018-12-05 Beth Israel Deaconess Medical Center, Inc. Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
WO2017004243A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
PT3353303T (pt) 2015-09-25 2023-10-10 Academisch Ziekenhuis Leiden Composições e métodos para modulação da expressão de ataxina 3
WO2017075432A2 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
CA3054284A1 (en) 2016-02-25 2017-08-31 The Brigham And Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
AU2017234678A1 (en) 2016-03-16 2018-08-16 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
CN109715802A (zh) 2016-03-18 2019-05-03 卡里斯科学公司 寡核苷酸探针及其用途
AU2017271579B2 (en) 2016-05-25 2023-10-19 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
CA3030701A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
EP3532638A4 (de) 2016-10-31 2020-07-29 University of Massachusetts Targeting von microrna-101-3p in der krebstherapie
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
US20200384115A1 (en) 2017-04-21 2020-12-10 The Broad Institute , Inc. Targeted delivery to beta cells
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3589658A1 (de) 2017-08-03 2020-01-08 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
CA3071033A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
CN111902537A (zh) 2018-01-15 2020-11-06 Ionis制药公司 Dnm2表达的调节剂
TW202000199A (zh) 2018-03-02 2020-01-01 美商Ionis製藥公司 Irf4 表現之調節劑
WO2019169243A1 (en) 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
CA3094816A1 (en) 2018-03-22 2019-09-26 Board Of Regents, The University Of Texas System Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
US11661601B2 (en) 2018-03-22 2023-05-30 Ionis Pharmaceuticals, Inc. Methods for modulating FMR1 expression
CA3095545A1 (en) 2018-03-30 2019-10-03 Rheinische Friedrich-Wilhelms-Universitat Bonn Aptamers for targeted activaton of t cell-mediated immunity
EP3772928A4 (de) 2018-04-06 2021-12-29 Children's Medical Center Corporation Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
US11365416B2 (en) 2018-04-11 2022-06-21 Ionis Pharmaceuticals, Inc. Modulators of EZH2 expression
BR112020021253A2 (pt) 2018-05-09 2021-02-02 Ionis Pharmaceuticals, Inc. compostos e métodos para redução da expressão de atxn3
EP3799604A4 (de) 2018-05-09 2022-09-07 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verminderung der fxi-expression
EP3807411A4 (de) 2018-06-14 2022-08-03 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verminderung der atxn3-expression
SG11202011864XA (en) 2018-06-27 2020-12-30 Ionis Pharmaceuticals Inc Compounds and methods for reducing lrrk2 expression
KR20210044771A (ko) 2018-07-02 2021-04-23 압타미르 테라퓨틱스, 인코포레이티드 인간 지방세포에 대한 치료제의 표적화 전달
SG11202100077PA (en) 2018-07-25 2021-02-25 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn2 expression
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3843845A4 (de) 2018-08-29 2022-05-11 University Of Massachusetts Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
AU2019342197A1 (en) 2018-09-21 2021-04-15 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
JOP20210108A1 (ar) 2018-11-15 2023-01-30 Ionis Pharmaceuticals Inc معدِّلات تعبير irf5
CA3128093A1 (en) 2019-01-31 2020-08-06 Ionis Pharmaceuticals, Inc. Modulators of yap1 expression
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
TW202045724A (zh) 2019-02-27 2020-12-16 美商Ionis製藥公司 Malat1表現之調節劑
CN117431244A (zh) 2019-03-29 2024-01-23 Ionis制药公司 用于调节ube3a-ats的化合物和方法
US11786546B2 (en) 2019-07-26 2023-10-17 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating GFAP
CN114555621A (zh) 2019-08-15 2022-05-27 Ionis制药公司 键修饰的寡聚化合物及其用途
US20220064638A1 (en) 2020-02-28 2022-03-03 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating smn2
CA3181546A1 (en) 2020-05-01 2021-11-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating atxn1
US20210381039A1 (en) 2020-05-29 2021-12-09 Front Range Biosciences, Inc. Methods and compositions for pathogen detection in plants
WO2022006019A1 (en) 2020-06-29 2022-01-06 Front Range Biosciences, Inc. Characterization of cannabis cultivars based on terpene synthase gene profiles
JP2023532518A (ja) 2020-06-29 2023-07-28 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｐｌｐ１を調節するための化合物及び方法
EP4136092A4 (de) 2020-11-18 2023-10-11 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation der angiotensinogenexpression
CA3223192A1 (en) 2021-06-18 2022-12-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024044352A1 (en) 2022-08-26 2024-02-29 The General Hospital Corporation Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
DE4110085A1 (de) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
CA2126691C (en) * 1991-12-24 2003-05-06 Phillip Dan Cook Gapped 2' modified oligonucleotides
AU3249793A (en) * 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
CA2126979A1 (en) * 1991-12-31 1993-07-22 Eliezer Rapaport Antiparasitic oligonucleotides active against drug resistant malaria
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
RU95104940A (ru) * 1992-07-27 1997-01-10 Хайбрайдон Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
JP3160105B2 (ja) * 1992-12-11 2001-04-23 三共株式会社 プシコフラノース及びプシコピラノース誘導体
EP0693123A1 (de) * 1993-03-31 1996-01-24 HYBRIDON, Inc. Veränderte Oligonukleotide mit verbesserter anti-grippe Aktivität
PT698092E (pt) * 1993-05-11 2007-10-29 Univ North Carolina Oligonucleótidos complementares de uma cadeia codificadora que combatem splicing aberrante e métodos para a sua utilização
EP0721503A1 (de) * 1993-09-28 1996-07-17 The General Hospital Corporation Gebrauch von "antisense"-oligonukleotiden zur modulierung des nerven-wachstums und zum umkehren von beta/a4-induzierte morphologie

Also Published As

Publication number Publication date
US5652356A (en) 1997-07-29
ES2315442T3 (es) 2009-04-01
EP1019428A2 (de) 2000-07-19
DK1019428T3 (da) 2003-09-22
WO1997006662A3 (en) 1997-06-19
US5773601A (en) 1998-06-30
ES2201198T3 (es) 2004-03-16
EP1340765A2 (de) 2003-09-03
WO1997006662A2 (en) 1997-02-27
AU6953896A (en) 1997-03-12
EP1340765B1 (de) 2008-10-15
US5973136A (en) 1999-10-26
EP1340765A3 (de) 2006-06-21
DE69628864T2 (de) 2004-05-06
JP4177455B2 (ja) 2008-11-05
JPH11512088A (ja) 1999-10-19
PT1019428E (pt) 2003-10-31
CA2229811C (en) 2012-01-03
ATE411333T1 (de) 2008-10-15
DE69637718D1 (de) 2008-11-27
EP1019428B1 (de) 2003-06-25
CA2229811A1 (en) 1997-02-27
ATE243706T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
DE69628864D1 (de) Invertierte chimäre und hybrid-oligonukleotide
EP0881914A4 (de)
EP1325019A4 (de) Antisense-modulation der clusterinexpression
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
PT1250455E (pt) Inibição anti-sentido da expressão da ptp1b
EP1117672A4 (de) Antisense-modulation der survivin-expression
EP1419168A4 (de) Antisense-modulation der expression von apolipoprotein b
EP1007555A4 (de) Tropoelastinderivate
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
EP1189918A4 (de) Antisense-modulation der integrin-beta-3-expression
EP1135402A4 (de) Antisense modulation der egr-1 expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
EP1390388A4 (de) Antisense-modulation der expression des interferon-gamma-rezeptors 1
EP1173458A4 (de) Antinsens modulierung der sra expression
EP1448762A4 (de) Antisense-modulation der expression des toll-ähnlichen rezeptors 4 erfindungsgebiet
WO2002097108A3 (en) Antisense modulation of dual specific phosphatase 5 expression
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
WO2003012123A3 (en) Antisense modulation of dual specific phosphatase 9 expression
DE59805112D1 (de) Chimäre oligonucleotide und ihre verwendung
WO2003050246A3 (en) Antisense modulation of nod1 expression
WO2003106646A3 (en) ANTISENSE MODULATION OF DOUBLE SPECIFIC PHOSPHATASE 4 EXPRESSION

Legal Events

Date Code Title Description
8364 No opposition during term of opposition